103961-78-0|ICI 195739|2-(2,4-Difluorophenyl)-1-(3-(4-(2,2,3,3-tetrafluoropropoxy)styryl)-1,2,4-triazol-1-yl)-3-(1,2,4-triazol-1-yl)propan-2-ol|-范德生物科技公司

ICI 195739

NMR下载 COA and HPLC MSDS下载
names：
2-(2,4-Difluorophenyl)-1-(3-(4-(2,2,3,3-tetrafluoropropoxy)styryl)-1,2,4-triazol-1-yl)-3-(1,2,4-triazol-1-yl)propan-2-ol
CAS号：
103961-78-0
MDL Number：
MF(分子式)： C24H20F6N6O2 MW(分子量)： 538.45
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	ICI 195739
英文别名	ICI 195739; D-0870; D0870; D 0870; DO870; Ici 195739; ICI195739;
CAS号	103961-78-0
Inchi	InChI=1S/C24H20F6N6O2/c25-17-4-7-19(20(26)9-17)23(37,10-35-14-31-13-33-35)11-36-15-32-21(34-36)8-3-16-1-5-18(6-2-16)38-12-24(29,30)22(27)28/h1-9,13-15,22,37H,10-12H2/b8-3+
InchiKey	FZEJTXCSLUORDW-FPYGCLRLSA-N
分子式 Formula	C24H20F6N6O2
分子量 Molecular Weight	538.45
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	ICI 195739(CAS:103961-78-0):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	ICI 195739 is newer antifungal agents, it inhibit neutrophil random migration, chemotaxis and hexose monophosphate shunt activity and depresse natural killer cell cytoxicity.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Urbina JA. Specific treatment of Chagas disease: current status and new developments. Curr Opin Infect Dis. 2001 Dec;14(6):733-4[1]Review. PubMed PMID: 11964893.

[2]Williams KJ, Denning DW. Termination of development of D0870. J Antimicrob Chemother. 2001 May;47(5):720-1. PubMed PMID: 11328795.

[3] Molina J, Urbina J, Gref R, Brener Z, Rodrigues Júnior JM. Cure of experimental Chagas' disease by the bis-triazole DO870 incorporated into 'stealth' polyethyleneglycol-polylactide nanospheres. J Antimicrob Chemother. 2001 Jan;47(1):101-4. PubMed PMID: 11152439.

[4] Molina J, Brener Z, Romanha AJ, Urbina JA. In vivo activity of the bis-triazole D0870 against drug-susceptible and drug-resistant strains of the protozoan parasite Trypanosoma cruzi. J Antimicrob Chemother. 2000 Jul;46(1):137-40. PubMed PMID: 10882704.

[5] Matsunaga T, Harada T, Hirata Z, Mitsui T, Murano H, Shibutani Y. D0870, an antifungal agent, induces reverse use-dependent QT prolongation in dogs. J Vet Med Sci. 2000 May;62(5):491-7. PubMed PMID: 10852397.

6: Matsunaga T, Harada T, Mitsui T, Murano H, Duffy PA, Aldridge A, Shibutani Y. Influences of catecholamines on the sudden death induced in dogs by an antifungal agent, D0870. J Electrocardiol. 2000 Apr;33(2):181-8. PubMed PMID: 10819411.7: Kojima M, Yamada H, Nakamura S, Kikuchi M, Nakanishii T, Takahashi Y, Mochizuki H, Mikami Y. Antifungal activities of D0870 against fluconazole-resistant Candida albicans. Nihon Ishinkin Gakkai Zasshi. 1999;40(4):209-15. Japanese. PubMed PMID: 10536307.8: Matsunaga T, Harada T, Harada T, Inokuma M, Mitsui T, Duffy PA, Aldridge A, Shibutani Y. QT prolongation and torsades de pointes induced by an antifungal agent, D0870, in conscious dogs. Toxicology. 1999 Feb 15;132(2-3):187-99. PubMed PMID: 10433382.9: McKillop D, Back DJ, McCormick AD, Evans JA, Tjia J. Preclinical and in vitro assessment of the potential of D0870, an antifungal agent, for producing clinical drug interactions. Xenobiotica. 1999 Apr;29(4):395-408. PubMed PMID: 10375008.10: Hood SV, Hollis S, Percy M, Atkinson G, Williams K, Denning DW. Assessment of therapeutic response of oropharyngeal and esophageal candidiasis in AIDS with use of a new clinical scoring system: studies with D0870. Clin Infect Dis. 1999 Mar;28(3):587-96. PubMed PMID: 10194083.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开